These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 7466117)

  • 1. [A psychometric study of a group of Parkinsonian patients].
    Gil R; Lefevre JP
    Rev Neurol (Paris); 1980; 135(12):903-22. PubMed ID: 7466117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of visual impairment on measures of cognitive function for children with congenital toxoplasmosis: implications for compensatory intervention strategies.
    Roizen N; Kasza K; Karrison T; Mets M; Noble AG; Boyer K; Swisher C; Meier P; Remington J; Jalbrzikowski J; McLeod R; Kipp M; Rabiah P; Chamot D; Estes R; Cezar S; Mack D; Pfiffner L; Stein M; Danis B; Patel D; Hopkins J; Holfels E; Stein L; Withers S; Cameron A; Perkins J; Heydemann P
    Pediatrics; 2006 Aug; 118(2):e379-90. PubMed ID: 16864640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. International collaborative study of intracytoplasmic sperm injection-conceived, in vitro fertilization-conceived, and naturally conceived 5-year-old child outcomes: cognitive and motor assessments.
    Ponjaert-Kristoffersen I; Bonduelle M; Barnes J; Nekkebroeck J; Loft A; Wennerholm UB; Tarlatzis BC; Peters C; Hagberg BS; Berner A; Sutcliffe AG
    Pediatrics; 2005 Mar; 115(3):e283-9. PubMed ID: 15741353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Parkinson's disease and mental deterioration. Apropos of 30 cases].
    Mouren P; Poinso Y; Oppenheim G; Mouren A; Nguyen Quang N
    Ann Med Psychol (Paris); 1983 Nov; 141(9):945-56. PubMed ID: 6666920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dementia and treatment with L-dopa in Parkinson's disease.
    Hietanen M; Teräväinen H
    Mov Disord; 1988; 3(3):263-70. PubMed ID: 3193964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis.
    Merello M; Nouzeilles MI; Arce GP; Leiguarda R
    Mov Disord; 2002 Jul; 17(4):795-8. PubMed ID: 12210878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mental impairment in Parkinson's disease. The role of anticholinergic drugs.
    Meco G; Casacchia M; Lazzari R; Franzese A; Castellana F; Carta A; Iannuccelli M; Agnoli A
    Acta Psychiatr Belg; 1984; 84(4):325-35. PubMed ID: 6507124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intellectual functioning in children with early shunted posthemorrhagic hydrocephalus.
    Lacy M; Pyykkonen BA; Hunter SJ; Do T; Oliveira M; Austria E; Mottlow D; Larson E; Frim D
    Pediatr Neurosurg; 2008; 44(5):376-81. PubMed ID: 18703883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Long-term prognostic factors in Parkinson's disease (author's transl)].
    Guillard A; Chastang C
    Rev Neurol (Paris); 1978 May; 134(5):341-54. PubMed ID: 725403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Depression and Parkinson's Disease: study of a series of 135 Parkinson's patients].
    Anguenot A; Loll PY; Neau JP; Ingrand P; Gil R
    Can J Neurol Sci; 2002 May; 29(2):139-46. PubMed ID: 12038469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
    Holloway RG; Shoulson I; Fahn S; Kieburtz K; Lang A; Marek K; McDermott M; Seibyl J; Weiner W; Musch B; Kamp C; Welsh M; Shinaman A; Pahwa R; Barclay L; Hubble J; LeWitt P; Miyasaki J; Suchowersky O; Stacy M; Russell DS; Ford B; Hammerstad J; Riley D; Standaert D; Wooten F; Factor S; Jankovic J; Atassi F; Kurlan R; Panisset M; Rajput A; Rodnitzky R; Shults C; Petsinger G; Waters C; Pfeiffer R; Biglan K; Borchert L; Montgomery A; Sutherland L; Weeks C; DeAngelis M; Sime E; Wood S; Pantella C; Harrigan M; Fussell B; Dillon S; Alexander-Brown B; Rainey P; Tennis M; Rost-Ruffner E; Brown D; Evans S; Berry D; Hall J; Shirley T; Dobson J; Fontaine D; Pfeiffer B; Brocht A; Bennett S; Daigneault S; Hodgeman K; O'Connell C; Ross T; Richard K; Watts A;
    Arch Neurol; 2004 Jul; 61(7):1044-53. PubMed ID: 15262734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH; Klasser M; Reichmann H
    Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Medical management and social status of elderly Parkinson patients].
    Vieregge P; Körtke D; Meyer-Bornsen C
    Z Gerontol; 1994; 27(4):260-9. PubMed ID: 7975817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A new levodopa benserazide preparation for Parkinson's disease with motor fluctuations refractory to standard L-dopa].
    Fernández Pardal MM; Gatto E; Micheli F; Casas Parera I; Diaz S
    Medicina (B Aires); 1991; 51(6):561-7. PubMed ID: 7476112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of body weight gain in patients with Parkinson's disease after subthalamic stimulation.
    Montaurier C; Morio B; Bannier S; Derost P; Arnaud P; Brandolini-Bunlon M; Giraudet C; Boirie Y; Durif F
    Brain; 2007 Jul; 130(Pt 7):1808-18. PubMed ID: 17535833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease].
    Maurel F; Lilliu H; Le Pen C
    Rev Neurol (Paris); 2001 May; 157(5):507-14. PubMed ID: 11438770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Modification of disturbed visual-spatial performance in patients with Parkinson's disease by treatment with L-dopa].
    Jacobi P; Schneider E; Gundelsheimer W; Fischer PA
    Nervenarzt; 1974 Nov; 45(11):588-94. PubMed ID: 4453348
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and safety of piribedil in early combination with L-dopa in the treatment of Parkinson's disease: a 6-month open study.
    Suwantamee J; Nidhinandana S; Srisuwananukorn S; Laptikultham S; Pisarnpong A; Chankrachang S; Bundhukul A
    J Med Assoc Thai; 2004 Nov; 87(11):1293-300. PubMed ID: 15825702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Slowing of oscillatory brain activity is a stable characteristic of Parkinson's disease without dementia.
    Stoffers D; Bosboom JL; Deijen JB; Wolters EC; Berendse HW; Stam CJ
    Brain; 2007 Jul; 130(Pt 7):1847-60. PubMed ID: 17412733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Testosterone therapy in men with Parkinson disease: results of the TEST-PD Study.
    Okun MS; Fernandez HH; Rodriguez RL; Romrell J; Suelter M; Munson S; Louis ED; Mulligan T; Foster PS; Shenal BV; Armaghani SJ; Jacobson C; Wu S; Crucian G
    Arch Neurol; 2006 May; 63(5):729-35. PubMed ID: 16682542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.